Jonathan Violin Biography and Net Worth

Jonathan Violin has deep experience aligning clinical and scientific evidence with strategies to efficiently finance discovery and development of novel therapeutics. He was the co-founder of privately-held Viridian Therapeutics and led the firm’s operations prior to its acquisition by miRagen Therapeutics (now Viridian Therapeutics, Inc., Nasdaq: VRDN). He previously served as founding CEO of two virtual drug discovery companies, Quellis Biosciences and Dianthus Therapeutics. Prior to that, Jonathan co-founded and helped lead Trevena Inc. from discovery research through clinical development and NDA submission, including multiple rounds of venture and public financing. Jonathan holds a Ph.D. from the Department of Pharmacology at the University of California, San Diego, an M.B.A. with a concentration in Health Sector Management from the Fuqua School of Business, and a B.S. in Chemical Pharmacology from Duke University.

What is Jonathan Violin's net worth?: The estimated net worth of Jonathan Violin is at least $6.53 million as of February 2nd, 2023. Dr. Violin owns 430,905 shares of Viridian Therapeutics stock worth more than $6,532,520 as of April 19th. This net worth approximation does not reflect any other investments that Dr. Violin may own. Learn More about Jonathan Violin's net worth.
How do I contact Jonathan Violin?: The corporate mailing address for Dr. Violin and other Viridian Therapeutics executives is 6200 LOOKOUT ROAD, BOULDER CO, 80301. Viridian Therapeutics can also be reached via phone at (617) 272-4600 and via email at [email protected]. Learn More on Jonathan Violin's contact information.
Has Jonathan Violin been buying or selling shares of Viridian Therapeutics?: Jonathan Violin has not been actively trading shares of Viridian Therapeutics over the course of the past ninety days. Most recently, Jonathan Violin sold 50,000 shares of the business's stock in a transaction on Thursday, February 2nd. The shares were sold at an average price of $36.80, for a transaction totalling $1,840,000.00. Following the completion of the sale, the insider now directly owns 430,905 shares of the company's stock, valued at $15,857,304. Learn More on Jonathan Violin's trading history.
Who are Viridian Therapeutics' active insiders?: Viridian Therapeutics' insider roster includes Kristian Humer (CFO), and Jonathan Violin (Insider). Learn More on Viridian Therapeutics' active insiders.
Are insiders buying or selling shares of Viridian Therapeutics?: During the last twelve months, Viridian Therapeutics insiders bought shares 1 times. They purchased a total of 476,190 shares worth more than $9,999,990.00. During the last twelve months, insiders at the sold shares 3 times. They sold a total of 4,643 shares worth more than $121,461.10. The most recent insider tranaction occured on January, 22nd when Director Fairmount Funds Management Llc bought 476,190 shares worth more than $9,999,990.00. Insiders at Viridian Therapeutics own 1.4% of the company. Learn More about insider trades at Viridian Therapeutics.
Information on this page was last updated on 1/22/2024.

Jonathan Violin Insider Trading History at Viridian Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
2/2/2023	Sell	50,000	$36.80	$1,840,000.00	430,905
6/1/2022	Sell	30,000	$12.20	$366,000.00	480,905
5/2/2022	Sell	30,000	$13.04	$391,200.00	510,905
4/4/2022	Sell	3,600	$18.93	$68,148.00	540,905
4/1/2022	Sell	26,400	$18.92	$499,488.00	540,905
2/3/2022	Sell	909	$19.16	$17,416.44
2/1/2022	Sell	16,751	$19.55	$327,482.05

Jonathan Violin Buying and Selling Activity at Viridian Therapeutics

Viridian Therapeutics Company Overview

Viridian Therapeutics, Inc., a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED. It also provides VRDN-006 a preclinical program for autoimmune disease. In addition, the company offers VRDN-006 and VRDN-008 a preclinical program for autoimmune disease. The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021.Viridian Therapeutics, Inc. was founded in 2010 and is headquartered in Waltham, Massachusetts.

Today's Range

Now: $15.16

$14.93

$15.75

50 Day Range

MA: $17.78

$15.08

$20.17

2 Week Range

Now: $15.16

$10.93

$30.30

Volume

580,684 shs

Average Volume

930,628 shs

Market Capitalization

$951.59 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.07

AI “wealth window” is closing soon!

From Paradigm Press | Ad

Today, I’m making my boldest prediction ever. Next-generation AI technology will create the first $100 TRILLION industry.

I put together this personal video [HERE]…